Cases
Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Securities Class Action
Overview
Overview
- Date:
- 1/26/2016
- Company Name:
- Sarepta Therapeutics, Inc.
- Stock Symbol:
- SRPT
- Status:
- Closed/Complete
NEW YORK, January 26, 2016 – Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) investors concerning whether the company’s officers and board of directors violated the federal securities laws.
On January 15, 2016, the U.S. Food and Drug Administration published a report concerning Sarepta’s pending drug application stating that “we cannot approve drugs for which substantial evidence of effectiveness has not been established.”
If you purchased Sarepta securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On January 15, 2016, the U.S. Food and Drug Administration published a report concerning Sarepta’s pending drug application stating that “we cannot approve drugs for which substantial evidence of effectiveness has not been established.”
If you purchased Sarepta securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.